Xeris Biopharma Holdings, Inc. / Fundamentals
Income statement
- Net revenue
€211.09M - Cost of goods sold
€39.82M - Gross profit
€171.27M - SG&A expenses
€148.88M - R&D expenses
€23.84M - EBITDA
€2.64M - D&A
€10.78M - EBIT
-€8.43M - Interest expenses
€25.87M - EBT
-€30.31M - Tax expenses
-€2.85M - Net income
-€27.46M
Cash flow statement
- Net deferred tax
-€2.85M - Non-cash items
-€18.09M - Changes in working capital
€7.33M - Operating cash flow
-€5.43M - Capex
€263.41K - Other investing cash flow
-€250.54K - Net investing cash flow
€16.85M - Total cash dividends paid
€0.00 - Issuance of common stock
€0.00 - Debt repayment
€0.00 - Other financing cash flow
€4.65M - Net financing cash flow
-€1.61M - Foreign exchange effects
€0.00 - Net change in cash
€4.98M - Cash at end of period
€50.87M - Free cash flow
-€5.17M
Balance sheet
- Cash and cash equivalents
€50.87M - Cash and short-term investments
€50.87M - Total receivables
€45.52M - Inventory
€57.73M - Other current assets
€5.12M - Total current assets
€159.23M - Property, plant & equipment
€23.76M - Goodwill
€19.61M - Intangible assets
€80.22M - Long-term investments
€3.54M - Other non-current assets
€805.66K - Total non-current assets
€127.93M - Total assets
€287.16M - Accounts payable
€8.12M - Short-term debt
€10.56M - Other current liabilities
€62.97M - Total current liabilities
€81.66M - Long-term debt
€215.42M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€6.65M - Total non-current liabilities
€222.07M - Total liabilities
€303.72M - Common stock
€13.73K - Retained earnings
-€586.02M - Other equity
-€20.59K - Total equity
-€16.56M - Total liabilities and shareholders' equity
€287.16M
Company information
- Market capitalization
€642.04M - Employees
394 - Enterprise Value
€911.79M
Company ratios
- Gross margin
-
81.1% Much better than peer group: -225.4% - EBITDA margin
-
1.2% Much better than peer group: -678,080.9% - EBIT margin
-
-4.0% Much better than peer group: -671,435.6% - EBT margin
-
-14.4% Much better than peer group: -374,656.2% - Net margin
-
-13.0% Much better than peer group: -463,466.7% - ROE
-
165.8% Much better than peer group: -40.0% - ROA
-
-9.6% Much better than peer group: -76.4% - Asset turnover
-
73.5% Much better than peer group: 14.7% - FCF margin
-
-2.7% Much better than peer group: -245,998.0% - FCF yield
-0.9% - Efficiency ratio
98.8% - Net sales per employee
-
€535.76K - Net income per employee
-
-€69.68K